The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Inclusion Criteria: * Age ≥ 18 years old. * Able to verbally confirm understanding of the trial risks, benefits, and treatment options of fexofenadine hydrochloride therapy. He/she or his/her legal representative must provide written informed consent prior to participating in the clinical trial. * Acute ST-segment elevation myocardial infarction (STEMI) occurring within 7 days, with diagnostic criteria including: i) Typical clinical symptoms: such as severe crushing pain in the retrosternal or precordial area, usually lasting more than 10-20 minutes, which may radiate to the left upper arm, jaw, neck, back, or shoulders, etc.; ii) Elevated serum cardiac troponin (cTn): at least one measurement above the upper limit of normal (99th percentile of the reference upper limit); iii) ST-segment elevation: new ST-segment elevation at the J point in 2 adjacent leads. * Echocardiography indicating segmental wall motion abnormalities. Exclusion Criteria: * Need for long-term use of fexofenadine hydrochloride or other H1 receptor inhibitors. * Previous coronary artery bypass grafting (CABG) surgery. * History of severe renal failure with estimated glomerular filtration rate (eGFR) \< 30 ml/min. * History of severe liver dysfunction. * History of concurrent severe infection, hepatobiliary obstruction, or malignant tumor. * Expected life expectancy of less than 2 years due to non-cardiac diseases. * Currently receiving immunosuppressive therapy. * Pregnant, potentially pregnant, or l…